C07AG01 - Labetalol |
Not porphyrinogenic |
NP |
Rationale
Alpha/beta-blocker. Several references stating non-porphyrinogenicity. Alpha/beta receptor blocker of choice in acute porphyria.
Chemical description
Alpha/beta - receptor blocking agent. Metabolized by CYP 2D6 dependent conjugation to glucuronide, excreted in urine and bile.Some oxidative metabolism may take place but a minor pathway. Less than 5% excreted in unchanged form in urine. Thunell, patient report (n=1): tolerated. Andersson, patient report (n=1): tolerated. South African list: use. French list: authorized. Kalman, Bonkowsky: believed to be safe. Michael Moore's list: safe. Moore MR, Hift RJ: Drugs in the acute porphyrias. Cell Mol Biol. 43:89, 1997: safe.
Similar drugs
References
| # | Citation details | PubMed ID |
|---|---|---|
| 1. | Management of acute attacks in the porphyrias.
Kalman DR, Bonkovsky HL. Clin Dermatol. 1998; 16(2):299-306.
|
9554242 |
| 2. | Drugs in the acute porphyrias--toxicogenetic diseases.
Moore MR, Hift RJ. Cell Mol Biol (Noisy-le-grand). 1997 Feb; 43(1):89-94.
|
9074793 |
| 3. | International review of drugs in acute porphyria--1980.
Moore MR. Int J Biochem. 1980; 12(5-6):1089-97.
|
7004930 |
Tradenames
Labetalol · Trandate 
Trandate 
Trandate 
Labetalol · Trandate 
Labetalolo · Trandate 
Trandate 
Trandate 
Labetalol · Trandate 
Labetalol · Trandate 
Albetol · Labetalol · Trandate 
Labetalol · Trandate 
Diblorec · Duobloq · Labetalol · Presequil · Trandate 
Albetol · Hybloc · Trandate 
Trandate · Trantalol 
Labetalol · Trandate 
Trandate 
Trandate 
Albetol · Labetalol 
Trandate 
Trandate 
Labetalol · Labetalolo · Trandate 
Labetalol · Trandate 
Labetalol